Autolus Therapeutics (NASDAQ:AUTL) Shares Climb 6.2% – Should You Buy?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shares traded up 6.2% on Wednesday. The stock traded as high as $1.98 and last traded at $1.9750. Approximately 450,965 shares changed hands during trading, a decline of 75% from the average session volume of 1,783,079 shares. The stock had previously closed at $1.86.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AUTL shares. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, August 3rd. Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Finally, Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Stock Performance

The business’s fifty day moving average is $2.02 and its 200-day moving average is $1.71. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The company has a market cap of $520.35 million, a PE ratio of -1.85 and a beta of 2.10.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06. The business had revenue of $45.69 million for the quarter, compared to the consensus estimate of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. As a group, research analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AUTL. QRG Capital Management Inc. grew its holdings in Autolus Therapeutics by 67.7% during the second quarter. QRG Capital Management Inc. now owns 18,325 shares of the company’s stock valued at $29,000 after purchasing an additional 7,400 shares during the period. GAMMA Investing LLC raised its stake in shares of Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after buying an additional 8,309 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in shares of Autolus Therapeutics by 2.5% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after buying an additional 11,197 shares in the last quarter. R Squared Ltd grew its stake in shares of Autolus Therapeutics by 48.4% during the 1st quarter. R Squared Ltd now owns 39,575 shares of the company’s stock valued at $55,000 after acquiring an additional 12,915 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Autolus Therapeutics by 55.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 44,053 shares of the company’s stock worth $88,000 after acquiring an additional 15,647 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc (NASDAQ: AUTL) is a biopharmaceutical company developing and commercializing programmed T-cell therapies for cancer and other serious diseases. The company uses genetic engineering to create CAR T-cell products designed to recognize and eliminate cancer cells while improving control, persistence and safety compared with earlier-generation cell therapies.

Autolus’ lead product, obecabtagene autoleucel, also known as obe-cel and marketed in the United States as AUCATZYL, is a CD19-directed autologous CAR T-cell therapy.